Corhythm

Corhythm develops an implantable treatment that detects the early onset of atrial fibrillation and chronic heart failures.

Corhythm Inc. engages in the development of an implantable treatment that detects early onset of atrial fibrillation and chronic heart failure. The company offers device that uses semiconductor technology to provide pacing and defibrillation, and delivers targeted medications when an atrial fibrillation is detected. The company was incorporated in 2007 and is based in San Jose, California.